Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Regular check-ins allow your care team to tailor the treatment to your specific needs and challenges
The decision to continue, taper, or stop should be individualized, not driven by arbitrary timelines
- People with significant liver disease (the 9-month monkey toxicology study showed dose-dependent periportal vacuolation in hepatocytes that the FDA flagged as a possible safety signal)
A reputable supplier should be willing to publish or provide third-party COAs (Certificates of Analysis) for each batch
Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
